The current state of breast cancer classification

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Viale, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Breast cancer; Classification; Immunohistochemistry; Molecular assays

Indexed keywords

HORMONE RECEPTOR; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; REPRODUCIBILITY; SYSTEMIC THERAPY; TREATMENT OUTCOME;

EID: 84866765384     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds326     Document Type: Article

References (27)

1. Ellis IO, Schnitt SJ, Sastre-garau X et al. Invasive breast carcinoma. In Tavassoli FA, Devilee P (eds), Tumours of the Breast and Female Genital Organs. Lyon: IARC Press 2003; 9-110.
2. Pestalozzi BC, Zahrieh D, Mallon E et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008; 26: 3006-3014.
3. Viale G, Rotmensz N, Maisonneuve P et al. Lack of prognostic significance of 'classic' lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat 2009; 117: 211-214.
4. Colleoni M, Rotmensz N, Maisonneuve P et al. Outcome of special types of breast cancer. Breast Cancer Res Treat 2012; 133: 713-723.
5. Arpino G, Clark GM, Mohsin S et al. Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer 2000; 94: 2119-2127.
6. Leibl S, Gogg-Kammerer M, Sommersacher A et al. Metaplastic breast carcinomas: are they of myoepithelial differentiation? Immunohistochemical profilke of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 2005; 29: 347-353.
7. Orvieto E, Maiorano E, Bottiglieri L et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 2008; 113: 1511-1520.
8. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
9. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
10. Carlson RW, Moench SJ, Hammond ME et al. NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006; 4(Suppl 3): S1-S22.
11. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 251: 118-145.
12. Gerdes J, Schwab U, Lemke H et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
13. Thor AD, Liu S, Moore DH et al. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 1999; 17: 470-477.
14. de Azambuja E, Cardoso F, de Castro G, Jr. et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer 2007; 96: 1504-1513.
15. Jonat W, Arnold N. Is the Ki-67 labelling index ready for clinical use? Ann Oncol 2011; 22: 500-502.
16. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. American Society of Clinical Oncology. J Clin Oncol 2007; 25: 5287-5312.
17. Dowsett M, Nielsen TO, A'hern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103: 1656-1664.
18. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
19. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
20. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
21. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
22. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
23. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 5222-5232.
24. Ellis MJ, Suman VJ, Hoog J et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype- ACOSOG Z1031. J Clin Oncol 2011; 29: 2342-2349.
25. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
26. Carey L, Winer E, Viale G et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010; 7: 683-692.
27. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011; 22: 1736-1747.